In-vitro activity of the novel oxa-beta-lactam antibiotic moxalactam (LY 127935) against dense populations of selected Gram-negative bacilli.
The activity of moxalactam, a new beta-lactam antibiotic with a novel molecular structure, was examined against dense populations of a variety of Gram-negative bacilli. The lytic activity of moxalactam against ampicillin-sensitive strains was similar to ampicillin, but the activity was maintained against ampicillin-resistant strains, including Pseudomonas aeruginosa, irrespective of whether the ampicillin resistance was 'intrinsic' (non-enzymic) or due to beta-lactamase. Of the 18 strains tested only one, a Hafnia sp., failed to respond to moxalactam.
D000667:Ampicillin / Q000494:pharmacology; D001419:Bacteria / Q000187:drug effects*; D002439:Cefotaxime; D002511:Cephalosporins / Q000494:pharmacology*; D002513:Cephamycins / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004755:Enterobacteriaceae / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D009070:Moxalactam; D013997:Time Factors
D002511:Cephalosporins; D002513:Cephamycins; D000667:Ampicillin; D002439:Cefotaxime; D009070:Moxalactam